Molecular MRD Monitoring Is Feasible in the Majority of Children with AML and Is Highly Predictive of Outcome: Results from the International MyeChild01 Study
Year: 2019
Type: conference-abstract
Source: Blood
Authors: Jelena Jovanovic, Nicola Potter, Anju Kanda, Claire Schwab, Aimee E Jackson, Richard Dillon, Anna Lawson, Manohursingh Runglall, Paresh Vyas, Paul Virgo, Geoff Shenton, Nicholas Heaney, Beki James, Katharine Patrick, Persis J Amrolia, Jean-Hugues Dalle, Gerard Michel, Andrew S. Moore, Hélène Lapillonne, Claude Preudhomme, Guy Leverger, Owen P Smith, Andre Baruchel, Yves Bertrand, Arnaud Petit, Keith Wheatley, Pamela R. Kearns, Christine J. Harrison, Brenda Gibson
Institutions: King's College London, Newcastle University, Cancer Research UK Clinical Trials Unit, University of Birmingham, University of Oxford, MRC Weatherall Institute of Molecular Medicine, North Bristol NHS Trust, Newcastle upon Tyne Hospitals NHS Foundation Trust, Royal Hospital for Children, Leeds Teaching Hospitals NHS Trust, Sheffield Children's Hospital, Great Ormond Street Hospital, Assistance Publique – Hôpitaux de Paris, Hôpital Robert-Debré, Aix-Marseille Université, The University of Queensland, Hôpital Armand-Trousseau, Centre Hospitalier Universitaire de Lille, Children's Health Ireland at Crumlin, Université Paris Diderot
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2988176726